Prime Capital Investment Advisors LLC Sells 22,177 Shares of Becton, Dickinson and Company $BDX

Prime Capital Investment Advisors LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 42.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 30,437 shares of the medical instruments supplier’s stock after selling 22,177 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $5,697,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. RiverGlades Family Offices LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth about $344,000. Transcend Capital Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 88.2% during the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after buying an additional 2,715 shares during the last quarter. Belpointe Asset Management LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $650,000. Finally, Strs Ohio increased its position in shares of Becton, Dickinson and Company by 31.7% in the third quarter. Strs Ohio now owns 301,430 shares of the medical instruments supplier’s stock valued at $56,419,000 after acquiring an additional 72,626 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BDX. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research report on Wednesday, January 28th. Finally, Citigroup assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday. They set a “buy” rating and a $233.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $213.36.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 2,463 shares of company stock valued at $501,530 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $210.45 on Friday. The company has a market cap of $59.96 billion, a P/E ratio of 36.10, a P/E/G ratio of 2.28 and a beta of 0.25. The firm’s fifty day moving average price is $199.83 and its two-hundred day moving average price is $192.22. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $235.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter in the previous year, the firm posted $3.81 EPS. Becton, Dickinson and Company’s revenue was up 8.3% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.